Avinger to Announce Third Quarter 2020 Results on November 10, 2020
Avinger, Inc. (NASDAQ:AVGR) will release its Q3 2020 financial results on November 10, 2020, after market close. A conference call is scheduled for 1:30 PM PT (4:30 PM ET) where details will be discussed. Avinger specializes in catheter-based systems for diagnosing and treating Peripheral Artery Disease (PAD), impacting over 12 million people in the U.S. The company aims to transform vascular disease treatment through its Lumivascular platform. A live webcast will be available on their investor relations page.
- Company specializes in innovative treatments for Peripheral Artery Disease.
- Upcoming financial results release indicates transparency and regular updates to investors.
- None.
REDWOOD CITY, CA / ACCESSWIRE / October 28, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
To join the call by telephone, please dial +1-201-689-8031. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at http://www.avinger.com.
A replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after completion of the call.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
SOURCE: Avinger, Inc.
View source version on accesswire.com:
https://www.accesswire.com/612565/Avinger-to-Announce-Third-Quarter-2020-Results-on-November-10-2020
FAQ
When will Avinger release its Q3 2020 financial results?
What is the significance of Avinger's Lumivascular platform?
How can I join Avinger's conference call for Q3 2020 results?
Where can I find Avinger's investor relations information?
